PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

PharmaTher Holdings Ltd. a clinical-stage psychedelics biotech company, is pleased to announce that it has applied with the U.S. Food and Drug Administration to receive Orphan Drug Designation for ketamine to treat Status Epilepticus, a rare neurological disorder requiring emergency treatment for a seizure.